Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer mCRPC
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
HoLEP prior to Radiation Therapy for Patients with LUTS/Retention and Concurrent Prostate Cancer
Study Type: Supportive Care
Phase: N/A
NCTID: NCT03802851
Principal Investigator:
Donald Neff
Pilot Trial of Ultra-Hypofractionated Radiation in Early Prostate Cancer
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT03486821
Principal Investigator:
Xinglei Shen
Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
Study Type: Health Services
Phase: III
NCTID: NCT03860961
Principal Investigator:
Ronald Chen
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy ADT in High Risk Prostate Cancer with Initial Phase I NADIR Randomized Phase II Trial of Niraparib with Standard Combination Androgen Deprivation Therapy ADT and Radiotherapy in High Risk Prostate Cancer with Initial Phase I
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Darolutamide Plus Androgen Deprivation Therapy ADT Compared To Placebo Plus ADT In Patients With High-Risk Biochemical Recurrence BCR Of Prostate Cancer
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician?s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01
Study Type: Treatment
Phase: III
NCTID: NCT06120491
Principal Investigator:
Elizabeth Wulff-Burchfield